Norvir (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, 'Norvir (HIV) - Forecast and Market Analysis to 2022'. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.Norvir (ritonavir) is a PI indicated in combination with other antiretroviral agents for the treatment of HIV infection. Unlike most PIs, which are prescribed due to their activity against the HIV protease, Norvir is commonly prescribed in combined with other protease inhibitors as a pharmacokinetic enhancer. Norvir increases the plasma levels of other PIs by inhibiting the cytochrome P450 enzyme CYP3A, which would otherwise decrease bioavailability and half-life of the PIs via metabolism (Norvir prescribing information, 2012). Therefore, while Norvir can be administered as an antiretroviral agent, the drug will be considered as a pharmacokinetic enhancer for the purposes of this report since the drug is predominately prescribed for that purpose. Scope - Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on Norvir including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for Norvir for the top nine countries from 2012 to 2022.- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for HIV- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of Norvir performance- Obtain sales forecast for Norvir from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Norvir (HIV) - Forecast and Market Analysis to 2022
Published on January 2013
Report Summary
Norvir (HIV) - Forecast and Market Analysis to 2022
Summary
GlobalData has released its new PharmaPoint Drug Evaluation report, 'Norvir (HIV) - Forecast and Market Analysis to 2022'. Human
Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of
antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most
infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases
infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug
regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of
single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and
patients alike by increasing clinical efficacy thresholds and enabling patient compliance.
Norvir (ritonavir) is a PI indicated in combination with other antiretroviral agents for the treatment of HIV infection. Unlike most PIs,
which are prescribed due to their activity against the HIV protease, Norvir is commonly prescribed in combined with other protease
inhibitors as a pharmacokinetic enhancer. Norvir increases the plasma levels of other PIs by inhibiting the cytochrome P450 enzyme
CYP3A, which would otherwise decrease bioavailability and half-life of the PIs via metabolism (Norvir prescribing information, 2012).
Therefore, while Norvir can be administered as an antiretroviral agent, the drug will be considered as a pharmacokinetic enhancer for
the purposes of this report since the drug is predominately prescribed for that purpose.
Scope
- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on Norvir including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Norvir for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Norvir performance
- Obtain sales forecast for Norvir from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil
and China)
Norvir (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Norvir (ritonavir) 23
6.1 Overview 23
6.2 Efficacy 24
6.3 Safety 24
6.4 SWOT Analysis 25
6.5 Forecast 26
7 Appendix 27
7.1 Bibliography 27
7.2 Abbreviations 29
7.3 Methodology 31
7.4 Forecasting Methodology 31
7.4.1 HIV Prevalence 31
7.4.2 Percent Drug-Treated Patients 31
7.4.3 General Pricing Assumptions 32
7.4.4 Individual Drug Assumptions 33
7.4.5 Generic Erosion 33
7.5 Physicians and Specialists Included in this Study 34
7.5.1 Survery of Prescribing Physicians 35
7.6 About the Authors 35
7.6.1 Authors 35
7.6.2 Global Head of Healthcare 36
7.7 About GlobalData 37
Norvir (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
7.8 Contact Us 37
7.9 Disclaimer 37
List of Tables
Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile ' Norvir 24
Table 6: Norvir SWOT Analysis, 2012 25
Table 7: Global Sales Forecasts ($m) for Norvir, 2012-2022 26
Table 8: Physicians Surveyed, By Country 35
List of Figures
Figure 1: HIV Lifecycle 11
Norvir (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Norvir (HIV) - Forecast and Market Analysis to 2022
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 6 995.00 Quantity: _____
Site License--USD 13 990.00 Quantity: _____
Corporate License--USD 20 985.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Norvir (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Norvir (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 5/5